Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This is an open, prospective and interventional clinical study. Patients with advanced Human
Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer resistant to trastuzumab
will be enrolled in the study. Histological specimens obtained from different metastatic foci
of patients, are used to conduct genome-wide sequencing together with Circulating tumor DNA
(ctDNA) of blood samples. Meanwhile, investigator will construct PDO model based on biopsy
tissue. Patients as well as their paired Patient-derived organoids (PDO) models are divided
into six groups according to genomic signatures. Each group of patients will receive the best
targeted treatment scheme from the current clinical perspective, while the matched PDO model
will accept a variety of potential effective schemes intervention. The future treatment plan
of patients will be timely adjusted based on the tumor inhibition rate of PDO models. This
study is the first time to explore the best individualized application sequence of targeted
therapy for refractory HER2 positive breast cancer by combining genome sequencing with drug
sensitivity test of PDO model. The results are expected to improve the prognosis of patients
with advanced HER2 positive breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University